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Abstract
Phosphorylation is considered a key event in the signalling and regulation of the μ opioid receptor 
(MOPr). Here we used mass spectroscopy to determine the phosphorylation status of the C-
terminal tail of the rat MOPr expressed in HEK-293 cells. Under basal conditions, MOPr is 
phosphorylated on Ser363 and Thr370, while in the presence of morphine or [D-Ala2, NMe-Phe4, 
Gly-ol5]-enkephalin (DAMGO), the COOH-terminus is phosphorylated at three additional 
residues, Ser356, Thr357, and Ser375. Using N-terminal Glutathione S Transferase (GST) fusion 
proteins of the cytoplasmic, C-terminal tail of MOPr and point mutations of the same, we show 
that, in vitro, purified G protein-coupled receptor kinase 2 (GRK2) phosphorylates Ser375, PKC 
phosphorylates Ser363 whilst CaMKII phosphorylates Thr370. Phosphorylation of the GST fusion 
protein of the C-terminal tail of MOPr enhanced its ability to bind arrestin-2 and -3. Hence, our 
study identifies both the basal and agonist-stimulated phospho-acceptor sites in the C-terminal tail 
of MOPr, and suggests that the receptor is subject to phosphorylation and hence regulation by 
multiple protein kinases.
Keywords
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Introduction
Phosphorylation of MOPr has been implicated in the desensitization and trafficking of the 
receptor, as well as in the development of opioid tolerance in the intact organism (Johnson et 
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al. 2005; Dang and Christie 2012; Kelly et al. 2008; Kelly 2011). The identity of 
phosphorylated amino acids in the intracellular regions of MOPr is therefore of considerable 
interest and importance. Using a [32P]orthophosphate metabolic prelabelling approach, in 
conjunction with site-directed mutagenesis, previous studies have identified amino acids in 
MOPr that are phosphorylated under basal conditions or in response to opioid agonist (Deng 
et al. 2000; El Kouhen et al. 2001; Wang et al. 2002; Schulz et al. 2004; Ozsoy et al. 2005; 
Wang et al. 2007; Chu et al. 2008). However there remains disagreement as to the identity 
of phosphorylated residues, as well as the role of such residues in the regulation of MOPr 
(Pak et al. 1997; Burd et al. 1998; Deng et al. 2000; El Kouhen et al. 2001; Wang et al. 
2002; Schulz et al. 2004; Johnson et al. 2005; Ozsoy et al. 2005; Wang et al. 2007; Chu et 
al. 2008). This may in part be due to the previous reliance on the use of MOPr point 
mutations to confirm phosphorylation data. Such mutations might influence receptor 
function in ways that are not related to the phosphorylation of that particular residue (Kim et 
al. 2005). A better approach would be the direct identification of phosphorylated residues in 
the receptor by mass spectrometry. This has been achieved for some G protein-coupled 
receptors (GPCRs) including the β2-adrenoceptor (Trester-Zedlitz et al. 2005; Nobles et al. 
2011), the V2 vasopressin receptor (Wu et al. 2008) and the CXCR4 receptor (Busillo et al. 
2010). In the case of opioid receptors, mass spectrometry has been employed to sequence 
the purified MOPr and KOPr (Christoffers et al. 2003; Wannemacher et al. 2008). Very 
recently it has also been applied to study the phosphorylation sites of the C-terminal tail of 
MOPr (Lau et al. 2011; Feng et al. 2011; Moulédous et al. 2012).
Apart from the identification of phospho-acceptor sites, the kinases that mediate these 
phosporylatyion events are generally not known. However G protein-coupled receptor 
kinases have been implicated in the phosphorylation of Ser375 (Schulz et al. 2004). Here we 
use Liquid Chromatography with Tandem Mass Spectrometry (LC-MS/MS) to identify 
phosphorylated amino acids in the cytoplasmic, C-terminal tail of MOPr. We find that this 
region of MOPr is phosphorylated on multiple residues both under basal conditions and 
upon stimulation by agonist. Furthermore, using GST fusion proteins of the C-terminal tail 
of the receptor we identify, in vitro, possible sites for phosphorylation by both GRK2 and 
second messenger-dependent protein kinases. Finally, we demonstrate that phosphorylation 
of the C-terminal tail of MOPr increases its ability to interact with arrestins.
Materials and Methods
Cell culture
HEK293 cells stably expressing MOPr (~0.5 pmol/mg membrane protein) tagged at the NH2 
terminus with hemagglutinin (HA) were grown in Dulbecco's Modified Eagle's medium 
(Invitrogen, Paisley, UK) supplemented with 10% foetal calf serum, 200 μg/ml geneticin 
(PAA, Pasching, Austria), 10 U/ml penicillin and 10 μg/ml streptomycin. For experimental 
purposes, cells were grown to approximately 90% confluence and incubated with 10 μM 
DAMGO, 30 μM morphine or with no drug for 10 min, washed twice in ice-cold phosphate 
buffered saline and scraped into lysis buffer (20 mM Tris/HCl pH7.4, 140 mM NaCl, 1 mM 
EDTA containing protease inhibitors (Complete; Roche Products, Welwyn Garden City, 
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UK) and phosphatase inhibitors (PhosStop; Roche Products)). Unless otherwise stated, all 
drugs, chemicals and kits were obtained from Sigma-Aldrich (Poole, UK).
Affinity purification of HA-tagged MOPr and tryptic digestion
A flowchart outlining the methodology is shown in Fig. 1A. Cells from 12 × 150 cm2 flasks 
were scraped into 25 ml lysis buffer and lysed with a Polytron homogeniser. Nuclei and cell 
debris were removed by centrifugation at 3,000 g for 5 min, and the supernatant was diluted 
to 50 ml with lysis buffer and subjected to centrifugation at 40,000 g for 1 h. The resultant 
membrane pellet was washed with lysis buffer and then dissolved in 5 ml lysis buffer 
containing 1% of the detergent NP40. Insoluble material was removed by centrifugation and 
the supernatant diluted 2-fold with 20 mM Tris/HCl pH 7.4, 140 mM NaCl. MOPr was 
immunoprecipitated by mixing with agarose beads coupled to anti-HA antibody (200 μl) 
(Roche Products) at 4°C overnight. Beads were then washed three times with 20 mM 
Tris/HCl pH7.4, 140 mM NaCl, 0.5% NP40. Bound proteins were eluted into SDS sample 
buffer and subjected to SDS-PAGE. The gel was stained with colloidal Coomassie blue and 
the band corresponding to MOPr (~80kD) was excised. (For the purposes of photography 
one gel was stained using the ProteoSilver™ Plus Silver Stain kit (Bio-Rad laboratories, 
Hemel Hempstead, UK) according to the supplier's instructions; see Fig. 1B). The gel slice 
was washed three times for 15 min with 100 mM ammonium bicarbonate. Reduction and 
alkylation of cysteine residues was performed by incubation of the gel slice in 50 mM 
ammonium bicarbonate containing 10 mM dithiothreitol at 60°C for 30 min followed by 
incubation in 50 mM ammonium bicarbonate containing 100 mM iodoacetamide for 30 min 
in the dark. Gel slices were washed 3 times for 5 min with 50 mM ammonium bicarbonate 
containing 50% acetonitrile and incubated overnight at 37°C in 50 mM ammonium 
bicarbonate containing 1 μg sequencing grade trypsin (Promega, Southampton, UK). The 
solvent was removed in a under vacuum in a centrifugal concentrator and the peptides 
redissolved in 0.1% triflouroacetic acid.
LC-MS/MS
LC-MS/MS was carried out upon each sample using an LTQ (Linear Trap Quadrupole) 
Orbitrap mass spectrometer by the Protein and Nucleic Acid Chemistry Laboratory at the 
University of Leicester. Briefly, peptides resulting from in-gel digestion were loaded at high 
flow rate onto a reverse-phase trapping column (0.3 mm i.d. × 1 mm), containing 5 μm C18 
300 Å Acclaim PepMap media (Dionex, Camberley, UK) and eluted through a reverse-
phase capillary column (75 μm i.d. × 150 mm) containing Symmetry C18 100 Å media 
(Waters, Elstree, UK). The output from the column was sprayed directly into the nanospray 
ion source of the LTQ Orbitrap mass spectrometer. The resulting spectra were analysed 
against the UniProtKB/SwissProt database using MASCOT software (Matrix Science Ltd., 
London, UK) with peptide tolerance set to 5 ppm and the MS/MS tolerance set to 0.6 
Daltons. Fixed modifications were set as carbamidomethyl cysteine with variable 
modifications of phosphoserine, phosphothreonine, phosphotyrosine and oxidised 
methionine. The enzyme was set to Trypsin/P and up to 2 missed cleavages were allowed. 
Peptides with a MASCOT score greater than 20 and where the probability (P) that the 
observed match was a random event was <0.05 were included in the analysis. The spectra of 
peptides reported as being phosphorylated were interrogated manually to confirm the precise 
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sites of phosphorylation. For each condition (i.e. plus DAMGO or morphine) the experiment 
was conducted 3 times and the results presented as a summary in Fig. 2.
GST-fusion protein expression and purification
The Glutathione-S-transferase (GST) fusion proteins, including GST-rat MOPr-2nd 
intracellular loop (GST-2IL), GST-rat MOPr-3rd intracellular loop (GST-3IL), and GST-rat 
MOPr C-terminal tail (GST-CT) were expressed in the pGEX-4T-1 vector. The sequences 
for MOPr-2IL, -3IL, and -CT were, respectively, 
S162VDRYIAVCHPVKALDFRTPRNAK185; 
L257RLKSVRMLSGSKEKDRNLRRITRMV282; 
N328SCLNPVLYAFLDENFKRCFREFCIPTSSTIEQQNSTRVRQNTREHPSTANTVDRT
NHQLENLEAETAPLP398. To generate a specific amino acid mutation in the GST fusion 
protein of MOPr-CT, the GeneTailor™ Site-Directed Mutagenesis System kit (Invitrogen, 
Paisley UK) was used. All the recombinant pGEX-4T-1 plasmids were transformed into 
BL21 (DE3) E. coli competent cells. Bacteria were grown in LB broth and protein 
expression induced by 0.5 mM isopropyl-beta-D-thiogalactopyranoside (IPTG; Apollo 
Scientific, Stockport UK) at 15°C overnight.
Bacterial cells were harvested by centrifugation at 5,040 g and 4°C for 15 min. The cell 
pellets were then resuspended in a lysis buffer (20 mM HEPES pH 7.4, 100 mM KCl) 
supplemented with 1 mM EDTA, 20 mM β-mercaptoethanol, 1 mM dithiothreitol, and 
protease inhibitors (0.5 mM benzamidine hydrochloride, 4 μg/ml leupeptin, and 4 μg/ml 
pepstatin), followed by 4 periods of sonication (30 sec each on dial 3, Misonix sonicator 
XL2020) to disrupt the cells. Triton-X 100 (1 % final concentration) was added to sonicated 
cells, followed by a further incubation at 4°C with gentle shaking to ensure efficient cell 
lysis. The unwanted pellets were removed by centrifugation of the lysate at 43,100 g at 4°C 
for 20 min. The supernatant containing the GST-fusion proteins was further incubated at 
4°C overnight, with a 50% slurry of glutathione sepharose 4B beads (GE Healthcare, 
Chalfont St Giles, UK), which had been prewashed and resuspended in lysis buffer. The 
GST-fusion protein-bound beads were then collected by a brief spin in a microcentrifuge, 
washed twice in lysis buffer, resuspended in 1 volume of lysis buffer and 2 volumes of 
glycerol and stored at -20°C.
Kinase-induced phosphorylation of GST fusion proteins
CaMKII requires activation by autophosphorylation before being used in the 
phosphorylation reaction. The activation reaction contained 1 μl (500 units) of CaMKII 
(New England BioLabs, Hitchin, UK) in the presence of 20 μM ATP, 1 mM calcium 
chloride, and 0.075 μM calmodulin in a final volume of 10 μl. Activation of the CaMKII 
mixture was performed at 30°C for 10 min to enable the autophosphorylation and hence 
activation of CaMKII.
The GST-fusion proteins immobilized on glutathione sepharose beads were washed and 
resuspended in assay buffer (20 mM HEPES pH7.4, 1 mM dithiothreitol) up to a final 
volume of 10 μl. The CaMKII-induced phosphorylation was initiated by incubating 5 μl of 
sample proteins in the presence of 10 μl of pre-activated CaMKII mixture, 5 μl of ATP 
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mixture (0.02 mM ATP, 10 mM MgCl2), and 2.8 μCi [γ-32P]ATP to a final volume of 25 μl. 
The final concentration of CaMKII was 100 nM. The phosphorylation reaction was allowed 
to proceed at 30°C for 15 min.
For PKC-induced phosphorylation, 5 μl washed beads were incubated with PKC 
(Calbiochem, Nottingham Uk, final concentration 100 nM), 5 μl ATP mixture, and 2.8 μCi 
[γ-32P]ATP, in a final volume of 25 μl at 30°C for 15 min.
For GRK2-induced phosphorylation, the washed beads were resuspended in 20 mM HEPES 
pH7.4, 1 mM dithiothreitol, and 1 mM EDTA. Reaction mixtures contained 5 μl sample 
protein, 100 nM GRK2 , 5 μl of ATP mixture, and 2.8 μCi of [γ-32P]ATP in a total volume 
of 25 μl and were incubated at 30°C for 15 min.
The kinase-induced phosphorylation reactions were stopped by the addition of 5 x SDS 
sample buffer to the reactions and heating at 100°C for 5 min. The proteins were then 
resolved by 12 % SDS-PAGE. The protein bands were visualized by staining with 
Coomassie blue; the gels with phosphorylated bands were visualised by autoradiography.
The software Image J (Rasband, W.S., ImageJ, U. S. National Institutes of Health, Bethesda, 
Maryland, USA, http://rsb.info.nih.gov/ij/, 1997-2009) was used to quantify the density of 
the phosphorylated bands on the autoradiograph, and the protein bands on the Coomassie 
blue-stained gel. The level of phosphorylation was quantified by normalizing the density of 
phosphorylated bands to the density of their corresponding protein bands, which represented 
the amount of protein used in each experiment. If no phosphorylated band was evident on 
the autoradiograph, the position corresponding to the protein band on the gel was identified 
and used in quantification. In the assays to identify phosphorylation sites for each kinase, 
after quantification as above, the phosphorylation level of each fusion protein containing the 
mutant MOPr sequence was compared to the phosphorylation level of the corresponding 
fusion protein containing WT sequence (taken as 100%).
Arrestin interaction with GST fusion proteins
Arrestin-2 and -3 were purified as previously described (Gurevich and Benovic, 2000; Zhan 
et al., 2011). GST fusion proteins on sepharose beads were made up to a total volume of 500 
μl in assay buffer (20 mM Tris, pH 7.5, 200 mM NaCl), and different amounts of purified 
arrestin-2 or arrestin-3 (final concentrations of 40, 200, 500, 1000, 1500 and 2000 ng/ml; 
2000 ng/ml is approximately equal to 44 nM) were added, and mixed by rotation at 4°C 
different lengths of time (30 min, 1 h or 2.5 h). Following the incubation, beads were 
recovered by centrifugation and washed three times with assay buffer and analysed by SDS-
PAGE. For Western blotting, proteins were transferred onto polyvinylidene fluoride 
membrane and the membrane stained with Ponceau S to determine the amount of GST-
fusion protein present. Following this the amount of arrestin-2 or -3 bound was determined 
using a rabbit polyclonal pan-arrestin antibody (1:3,000 dilution; Abcam, Cambridge, UK) 
and a donkey anti-rabbit IgG horseradish peroxidase (HRP)-linked secondary antibody 
(1:12,000 dilution; GE Healthcare). Amounts of GST-fusion protein and arrestin-2 or -3 
present on membranes, were quantified using Image J.
Chen et al. Page 5
J Neurochem. Author manuscript; available in PMC 2014 November 10.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Statistics
An unpaired t test was further used to compare the phosphorylation of GST fusion proteins 
to that of GST alone. A one-sample t test was used to compare the phosphorylation of 
mutants to the wild type GST fusion proteins, and to compare the binding of arrestins to 
different GST fusion proteins, and to phosphorylated and non-phosphorylated fusion 
proteins. Differences were regarded as significant when p < 0.05.
Results
Identification of phosphorylation sites in the C-terminal tail of MOPr in intact cells
When MOPr was affinity purified from HEK293 cells and subjected to SDS-PAGE, a band 
at the expected molecular weight for the rat MOPr (~ 80kDa) was observed (Fig. 1B). Mass 
spectrometric analysis of the purified MOPr identifed a series of peptide derived from the 
intracellular C-terminal tail. MS/MS sequencing of these peptides provided coverage of the 
entire C-terminal tail and identified a number of phospho-acceptor sites (Fig. 2 and see 
Supplementary Fig. 1). To assess the selective phosphorylation on the C-terminal tail of 
MOPr under basal and agonist-stimulated conditions, the HEK293 cells stably expressing 
HA-MOPr were incubated in the absence or presence of saturating concentrations of 
DAMGO (10 μM) or morphine (30 μM) for 10 min. Under basal conditions, Ser363 and 
Thr370 were found to be phosphorylated. In replicate 1, a singly phosphorylated peptide 
corresponding to the sequence around Ser363 was present but it was not possible to 
distinguish whether it was phosphorylated on Ser363 or Thr364. However, the MS/MS 
spectra generated in replicate 2 clearly showed the site to be Ser363.
On stimulation of the receptor with either morphine or DAMGO, these residues were still 
phosphorylated and three additional phosphorylation sites were found on Ser356, Thr357 and 
Ser375 (Fig. 2A). A summary of phosphorylated residues in the C-terminal tail of MOPr is 
shown in Fig. 2B.
GRK2 and second messenger-dependent protein kinases phosphorylate distinct residues 
on the C-terminal tail of MOPr expressed as a GST fusion protein
We investigated the in vitro ability of CaMKII, PKC and GRK2 to phosphorylate GST 
fusion proteins of the MOPr C-terminal tail in vitro using [γ-32P]-ATP incorporation. In 
preliminary experiments, we tested the ability of these kinases to phosphorylate the 2nd and 
3rd intracellular loops of MOPr in comparison to the C-terminal tail. All three kinases were 
able to phosphorylate intracellular regions of MOPr expressed as GST-fusion proteins, 
whilst GST alone was not phosphorylated by any of the kinases (Fig. 3). Notably the 
GST-3IL was markedly phosphorylated by each kinase, whilst phosphorylation of the GST-
CT was also observed with the kinases, with GRK2 being particularly effective in 
phosphorylating this region (Fig. 3). The specificity of CaMKII- and PKC-induced 
phosphorylation was confirmed with the selective inhibitors KN93 (10 μM) or GF109203X 
(10 μM), respectively (Supplementary Fig. 2A and B).
Further experiments were directed at identifying the phosphorylated residues in the COOH 
terminal tail of MOPr, since this region is mostly associated with receptor regulation (Kelly 
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2011). Point mutations were introduced into GST fusion proteins at residues likely to 
undergo phosphorylation. These experiments (Fig. 4) indicated clearly that, under these in 
vitro conditions, Thr370 is the main substrate for CaMKII phosphorylation, Ser363 the main 
substrate for PKC phosphorylation, and Ser375 the main substrate for GRK2 
phosphorylation. In addition, CaMKII-induced phosphorylation of the Ser363Ala mutant was 
moderately but significantly increased, whilst PKC-induced phosphorylation of the 
Ser356Ala/Ser357Ala double mutant was moderately but significantly reduced.
Arrestin-2 and -3 binding to the intracellular regions of MOPr
The ability of arrestin-2 and -3 to bind to GST fusion proteins of the intracellular regions of 
MOPr in vitro was also examined. In preliminary experiments, the interaction of purified 
arrestin-2 or -3 with GST-CT was shown to be concentration- and time-dependent 
(Supplementary Fig. 3 and 4), the latter being similar to that previously reported for arrestin 
interaction with other GPCRs (Gurevich et al., 1995). The ability of purified arrestins to 
interact with the intracellular regions of MOPr was then tested. Interestingly, whereas 
arrestin-3 bound avidly to GST-2IL and GST-3IL as well as GST-CT (Fig. 5C and D), 
arrestin-2 interacted much more readily with the C-terminal tail fusion protein than with 
those of the intracellular loops (Fig. 5A and B). We also tested the ability of GST-CT to 
interact with arrestins following phosphorylation by GRK2, PKC or CaMKII. The fusion 
protein was phosphorylated by the kinases as described above. Following this in vitro 
phosphorylation, the GST fusion protein was incubated with arrestin-2 or arrestin-3. Under 
these conditions phosphorylation by each of the three kinases enhanced the ability of 
arrestin-2 and -3 to bind to the GST fusion protein of MOPr, with the greatest increase in 
interaction being seen following GRK2 phosphorylation (Fig. 6).
Discussion
These results provide unequivocal identification of phosphorylated residues in the C-
terminal tail of MOPr expressed in HEK293 cells. The key findings of this work are that in 
these cells MOPr is phosphorylated in the absence of agonist; that DAMGO- and morphine-
induced phosphorylation involves multiple but similar residues in the C-terminal tail; that in 
vitro three kinases, CaMKII, PKC, and GRK2 phosphorylate distinct residues in the C-
terminal tail of MOPr; that in vitro arrestin-2 and -3 interact with the C-terminal tail of 
MOPr, and that this interaction is increased following kinase-induced phosphorylation of the 
protein.
A cluster of four amino acids (Thr354Ser355Ser356Thr357; refer to Fig. 2B) in the C-terminal 
tail of MOPr was previously reported to mediate agonist-induced desensitization of receptor 
responsiveness (Wang 2000), with Ser355 and Thr357 in particular being identified as likely 
phosphoacceptor sites (Wang et al., 2002). However others have reported that this cluster is 
not involved in either agonist-induced phosphorylation or desensitization of MOPr (Deng et 
al. 2000; El Kouhen et al. 2001). Here we confirm that Thr357 is phosphorylated in response 
to agonist and also identify Ser356 as a phosphorylated residue, rather than Ser355 as 
suggested previously (Wang et al. 2002). Furthermore our in vitro 32P-incorporation 
experiments identify PKC as a possible kinase for one or both of these sites, however it is 
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also possible that mutation on this Ser/Thr pair instead affects the PKC-induced 
phosphorylation of the nearby Ser363.
On the basis of point mutations, Ser363 and Thr370 in the C-terminal tail of MOPr were 
suggested to be phosphoacceptor sites (El Kouhen et al. 2001). The present results using 
mass spectrometry confirm this and, in addition, demonstrate that these residues can be 
phosphorylated in the absence of agonist treatment. However this does not preclude the 
possibility that these residues are further phosphorylated in the presence of agonist. A recent 
study (Doll et al. 2011) with antiphosphoreceptor antibodies also identifies Ser363 and 
Thr370 as phosphoacceptor residues, although these authors concluded that Thr370 was only 
phosphorylated in response to DAMGO, and not with morphine or under basal conditions. 
Another recent study (Feng et al. 2011) indicated that phorbol ester-induced desensitization 
of MOPr is mediated by PKC-dependent phosphorylation of Ser363. Interestingly using the 
in vitro GST fusion protein 32P-incorporation assay, we now show that Ser363 and Thr370 
are preferentially phosphorylated by PKC and CaMKII, respectively. MOPr has been 
suggested to be pre-phosphorylated by PKC (Johnson et al. 2006), which may underlie the 
ability of morphine to induce MOPr desensitization in neurones (Bailey et al. 2009a; Bailey 
et al. 2009b). In addition CaMKII activation has been implicated in morphine tolerance 
(Mestek et al. 1995; Koch et al. 1997; Fan et al. 1999). It remains to be seen whether or not 
such effects are indeed due to phosphorylation of these residues on MOPr by these second 
messenger-dependent kinases, or instead due to phosphorylation of other cellular substrates 
that contribute to morphine tolerance.
An anti-phosphoserine375 antibody has been developed and its use has already demonstrated 
that Ser375 is phosphorylated in an agonist-dependent manner (Schulz et al. 2004; Chu et al. 
2008; McPherson et al. 2010). We confirm here that this residue is indeed phosphorylated in 
response to agonist. Mutation of this Ser375 has been reported to inhibit agonist-induced 
desensitization (Ozsoy et al. 2005; Chu et al. 2008) and internalization of MOPr (El Kouhen 
et al. 2001), although in another study this mutation inhibited morphine- but not DAMGO-
induced desensitization (Schulz et al. 2004), whilst in yet other studies MOPr constructs 
with multiple mutations including of Ser375 were still able to undergo agonist-induced 
desensitization similar to the wild type MOPr (Pak et al. 1997; Deng et al. 2000). Clearly 
the precise role of Ser375 and its phosphorylation in MOPr function requires further study. 
On the other hand, Ser375 has been suggested to be the phosphorylation site for GRK2 
(Schulz et al., 2004) and in vitro phosphorylation data from the present study suggests that 
GRK2 is the likely kinase involved, although other GRKs may also be involved in vivo. In 
addition the ability of GRK2 to phosphorylate the agonist-occupied receptor is likely to be 
much greater than its ability to phosphorylate receptor fusion protein sequences (Benovic et 
al., 1990). A recent study identifies further phosphoacceptor sites in a cluster (S375TANT) 
around Ser375 including Thr376 and Thr379 (Lau et al. 2011; Moulédous et al. 2012); 
phosphorylation of these residues was associated with arrestin interaction with MOPr (Lau 
et al. 2011). However with regard to the data in the present study, it will be interesting to 
assess the effect of mutating the residues whose phosphorylation is agonist-dependent 
(Ser356, Thr357 and Ser375), on agonist-induced desensitization and trafficking of MOPr.
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On the basis of mutation data Thr394 has been identified in more than one study as a possible 
phosphoacceptor site (Pak et al. 1997; Deng et al. 2000). We were unable to detect 
phosphorylation of this residue, strongly suggesting that Thr394 is not phosphorylated. 
However with our present data we cannot absolutely rule out Thr394 as a phosphoacceptor 
site since it remains theoretically possible that the relevant phosphopeptide was missed in 
our analysis, but it is noteworthy that phosphorylation in the distal section of the COOH-
terminus of MOPr was not detected in other recent studies (Lau et al. 2011; Moulédous et 
al. 2012). Mutation of Thr394 has also been reported to markedly reduce agonist-induced 
desensitization and down regulation of MOPr (Pak et al. 1997; Deng et al. 2000), whilst a 
mutant MOPr with Thr394 mutated to alanine displays increased internalization and 
resensitization (Wolf et al. 1999). However, if Thr394 is not phosphorylated, then it is 
possible that this residue or the region of the COOH-terminus around it has some wider role 
in controlling MOPr function, such as a permissive role in kinase recruitment or perhaps this 
region of MOPr interacts with scaffolding proteins that are important for appropriate 
receptor regulation. The latter is supported by the finding that mutation of three glutamate 
residues close to Thr394 also inhibited MOPr desensitization (Pak et al. 1997).
With regard to the GST-fusion protein phosphorylation data in this study, it should be noted 
that the phosphorylation of a peptide by a particular kinase may not always reflect events in 
the intact cell. In addition the potential interaction of the C-terminal tail of the intact MOPr 
with other intracellular regions of the receptor, or with interacting proteins or even the 
membrane itself could influence the nature and extent of phosphorylation. These potential 
influences would be absent in the GST-fusion protein experiments. Furthermore, there is the 
question of the cellular activation of the three kinases identified as mediating the 
phosphorylation of the C-terminal tail. Whilst there is clear evidence that following MOPr 
activation, GRK (Doll et al. 2012) and PKC (Chu et al. 2010) are activated, there is less 
evidence to implicate CaMKII (Mestek et al. 1995, Sanchez-Blazquez et al. 2008), although 
in the intact brain these kinases could be activated by ongoing neuronal activity and 
consequent increases in intracellular free Ca2+; such a mechanism would give rise to 
heterologous regulation of MOPr. Furthermore the present results report phosphorylation of 
MOPr expressed in HEK293 cells, but it is possible that the receptor phosphorylation profile 
would be different in another cellular context such as neurones (Tobin et al. 2008; Torrecilla 
et al. 2007). Nevertheless it is of interest that morphine-induced desensitization of MOPr in 
the locus coeruleus requires ongoing PKC activity (Bailey et al. 2009a; Bailey et al. 2009b), 
suggestive of the possibility that basal MOPr phosphorylation also occurs in neurones. It is 
also possible that MOPr is phosphorylated at intracellular sites in addition to the C-terminal 
tail; for example Thr180 in the third intracellular loop of MOPr has been suggested to be a 
GRK phosphorylation site (Celver et al., 2001).
Previous studies have suggested that non-visual arrestins interact poorly if at all with the 
intracellular regions of MOPr (Cheng et al. 1998; Cen et al. 2001), although our recent work 
indicates that arrestin-3 does associate with intact MOPr in intact cells in an agonist-
dependent manner (McPherson et al. 2010). In the present study we found a robust 
interaction between purified arrestins and GST fusion proteins, with both arrestin-2 and -3 
being able to associate with the GST fusion protein of the C-terminal tail of MOPr. 
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Interestingly we found that phosphorylation of the GST-CT increased its interaction with 
each arrestin. Under the conditions of the assay GRK2 phosphorylation produced the 
greatest increase in arrestin association. Whether or not phosphorylation of Ser363 or Thr370 
affect arrestin association or MOPr trafficking in intact cells is less clear, but it should be 
noted that Ser363 is basally phosphorylated but does not lead to constitutive arrestin 
association with the receptor (Zhang et al., 1998; McPherson et al., 2010). Indeed, mutation 
of Ser363 actually enhances agonist-induced internalization of MOPr (El Kouhen et al. 
2001). On the other hand previous studies have shown that GPCRs normally require 
phosphorylation of two or more residues for tight binding of arrestins to occur (Gurevich et 
al., 1995; Vishnivetskiy et al., 2007), perhaps explaining the inability of arrestin to associate 
with the basally-phosphorylated MOPr in intact cells. Recent work also indicates that 
dependency on GPCR phosphorylation versus receptor activation for arrestin association is 
receptor subtype-dependent (Gimenez et al. 2012). The present results and those from other 
studies (Lowe et al., 2002; Lau et al. 2011; see references in Gurevich and Gurevich, 2006) 
suggest that arrestin association with the C-terminal tail of MOPr as well as other GPCRs 
has both phosphorylation-dependent and phosphorylation-independent components.
In conclusion, we have identified phosphorylated residues in the C-terminal tail of the rat 
MOPr stably expressed in HEK293 cells by LC-MS/MS. We have also identified candidate 
kinases for the phosphorylation of some of these residues, and show that phosphorylation by 
a range of protein kinases can enhance the association of arrestins with MOPr. Together 
these findings support the idea that MOPr signalling and regulation can be modulated by 
multiple kinase-dependent mechanisms.
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Fig. 1. 
(A) Flow diagram of methodology for MOPr purification and preparation for LC-MS/MS. 
(B) Gel stained with ProteoSilver™ Plus Silver Stain to demonstrate purity of the MOPr 
preparation.
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Fig. 2. 
Identity of phosphorylated residues in MOPr. (A) MOPr phosphopeptides obtained in the 
presence or absence of morphine or DAMGO. Phosphorylated Ser or Thr residues are 
denoted by larger red letters. Spectra were analysed against the UniProtKB/SwissProt 
database using MASCOT software with peptide tolerance set to 5 ppm and the MS/MS 
tolerance set to 0.6 Daltons. The spectra of peptides reported as being phosphorylated were 
interrogated manually to confirm the precise sites of phosphorylation. (B) Summary of 
phosphorylation sites in the MOPr C-terminal tail. The phosphorylated Ser or Thr residues 
(Ser356, Thr357, Ser363, Thr370, and Ser375) are underlined, as is the NPXXY motif, at the 
base of the 7th transmembrane domain where the C-terminus begins. The mass spectrometry 
experiments described here were carried out three times for each condition. The data 
presented is a summary of these experiments and the spectra shown in Supplementary Fig. 1 
are representative of the results obtained.
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Fig. 3. 
In vitro phosphorylation of intracellular regions of MOPr. GST fusion proteins (GST alone, 
GST-2IL, GST-3IL, GST-CT) immobilized on glutathione-Sepharose beads were incubated 
with purified CaMKII (preactivated), PKC, or GRK2 in the presence of [γ32P]ATP. 
Following SDS-PAGE, kinase-induced phosphorylation was detected by autoradiography 
(top panels), whilst the relative amounts of GST-fusion proteins were determined with 
Coomassie blue (middle panels). Bar graphs showing quantitation of phosphorylation are 
shown (bottom panels). Values are means ± SEM from 3-4 independent experiments in each 
case. All three kinases produced significant phosphorylation of the 3rdIL and CT of MOPr 
(unpaired t test, *** p < 0.001, ** p < 0.01 compared to GST alone).
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Fig. 4. 
Identification of In vitro phosphorylation sites in the C-terminal tail of MOPr. GST fusion 
proteins (wild type and mutant) immobilized on glutathione-Sepharose beads were 
incubated with purified CaMKII (preactivated), PKC, or GRK2 in the presence of 
[γ32P]ATP. Following SDS-PAGE, kinase-induced phosphorylation was detected by 
autoradiography (top panels), whilst the relative amounts of GST-fusion proteins were 
determined with Coomassie blue (middle panels). Bar graphs showing quantitation of 
phosphorylation relative to wild type (CT) constructs are shown (bottom panels). Values are 
means ± SEM from 3-4 independent experiments in each case. CaMKII phosphorylation 
was significantly reduced in the Thr370Ala mutant, PKC phosphorylation in the Ser363Ala 
mutant, and GRK2 phosphorylation in the Ser375Ala mutant (one sample t test, *** p< 0.001 
compared to respective wild type). PKC phosphorylation was also reduced in the 
Ser356Ala/Thr357Ala double mutant (* p< 0.01 compared to respective wild type), whilst 
CaMKII phosphorylation was increased in the Ser363Ala mutant (* p< 0.01 compared to 
respective wild type).
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Fig. 5. 
Arrestin-2 and -3 interaction with GST fusion proteins of the intracellular regions of MOPr. 
Purified (A, B) arrestin-2 or (C, D) arrestin-3 (final concentration 500 ng/ml in each case, 
approximately 11 nM) was incubated with GST alone or with GST-2IL, GST-3IL or GST-
CT. Example blots are shown in (A) and (C), whilst bar graps of data from 3-4 experiments 
are shown in (B) and (D). These results are shown as a % of arrestin binding to the GSTCT, 
taken as 100%, with error bars representing S.E.M. * p < 0.05 compared to binding of 
relevant arrestin to GST-CT, one-sample t test.
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Fig. 6. 
Phosphorylation increases the interaction of arrestin-2 and -3 with the GST-fusion protein of 
the C-terminal tail of MOPr. The GST-CT was subjected to phosphorylation by CaMKII, 
PKC, or GRK2 as described in the Methods section and their ability to interact with 
arrestin-2 or -3 (final concentration 500 ng/ml in each case, approximately 11 nM) was 
compared with that for nonphosphorylated GST-CT. Representative blots of the interaction 
of arrestin-2 (A) and arrestin-3 (B) with the non-phosphorylated and GRK2-phosphorylated 
GST-CT are shown, as well as (C) a bar graph showing data from at least 4 independent 
experiments. In all cases, phosphorylation increased arrestin-2 and arrestin-3 binding to the 
GST-CT. These results are shown as a % of arrestin binding to the non-phosphorylated 
GST-CT, taken as 100%, with error bars representing S.E.M. * p < 0.05 compared to 
binding of relevant arrestin to non-phosphorylated GST-CT (taken in each case as 100%), 
one-sample t test.
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